Voyager Therapeutics Inc (VYGR)
Voyager Therapeutics Inc (NASDAQ-VYGR) is a NASDAQ-listed biotechnology company whose common stock reflects an operating-company equity security. The company is associated with research and development work in neurological and central nervous system disorders, using gene therapy and related platform approaches. Its business is organized around early-stage scientific programs, discovery tools, and collaboration-driven development activities rather than a diversified consumer or industrial model. As common equity, VYGR represents ownership in the company and is not a fund, note, or other pooled investment vehicle. Investors should view it as a healthcare-sector stock tied to biotechnology research and development risk.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VYGR
|
$3.75
|
20.8% Upside
|
Undervalued
|
$14.89
|
379.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-1.6x
|
1.1x
|
5.2x
|
184.3 M
|
51.723 M
|
15.8%
|
73.2%
|
-1.6
|
—
|
111.4%
|
